We are seeking investors and partners to join with us in raising capital toward the following industry solutions:
JUNOKANA Integrated Medical Cannabis Platform
A first-of-its-kind solution for testing efficacy of medical cannabis in humans, making medical cannabis clinical use-cases measurable and providing a standardized point of reference for cannabis-based product development. JUNO Metabolomics is currently assisting customers seeking FDA approval.
JUNO Rapid SARS CoV-2 Solution - JunoCovid-Dx
A rapid, mobile metabolomics-based solution for diagnosing Covid-19 at scale that accounts for genetic viral mutations, enables personalized treatment and prevention, and tracks / predicts outbreaks via AI-enhanced automated data tracing. JUNO Metabolomics is partnering with U.S. military healthcare organizations in order to bring mass-testing capability to the armed forces and general public.